Curcumin for Menopause

Curcumin has not been shown to ease menopause as a whole. In three placebo-controlled trials that measured overall menopause symptoms or menopause-specific quality of life, curcumin did no better than placebo (Ataei-Almanghadim 2020; Farshbaf-Khalili 2022; Buntoonprayuk 2026), and a 2025 systematic review of 12 trials found no significant effects on physical, psychological or sexual function (Akyakar 2025).

A few narrower results are more encouraging. Two small trials found fewer hot flashes (Ataei-Almanghadim 2020; Buntoonprayuk 2026), one found less fatigue and better musculoskeletal scores (Shabani 2025), and a 2025 meta-analysis of 14 trials pooled improvements in blood pressure, antioxidant markers and vasomotor symptoms, but its authors called the conclusions limited because curcumin purity and dose varied between trials (Jin 2025). Most of the trials come from one Iranian research group, and none lasted longer than 12 months.

The trials started from the idea that falling estrogen at menopause switches on oxidative and inflammatory processes that drive symptoms, and that curcumin's antioxidant and anti-inflammatory effects might counter them (Farshbaf-Khalili 2022). The 2025 systematic review framed curcumin's possible benefits the same way (Akyakar 2025).

In one Iranian trial of 84 women given 500 mg curcumin twice a day for 8 weeks, malondialdehyde (a marker of oxidative damage, P = 0.009) and hs-CRP (an inflammation marker, P = 0.025) fell and total antioxidant capacity rose (P < 0.001) within the curcumin group; the abstract reports these as within-group changes, not differences from placebo (Farshbaf-Khalili 2022). Pooled across trials, curcumin raised total antioxidant capacity and superoxide dismutase (Jin 2025).

Better blood markers did not translate into fewer symptoms. In the trial where oxidative and inflammatory markers improved with curcumin, menopause symptom scores fell in every group, placebo included, and the only between-group symptom difference was less anxiety with vitamin E (Farshbaf-Khalili 2022).

Curcumin is also not a plant estrogen in any proven sense. The 2025 systematic review found conflicting results on estradiol levels (Akyakar 2025), and in one 6-month trial estradiol rose within the nanomicelle curcumin group, but only Nigella sativa raised it significantly compared with placebo (Sadeghzadeh 2023).

The most common regimen, used in four Iranian trials, was 500 mg curcumin capsules twice a day for 8 weeks (Ataei-Almanghadim 2020; Farshbaf-Khalili 2022; Yousefi-Nodeh 2024; Shabani 2025). A Thai pilot used 1,000 mg of curcuminoids a day for 12 weeks (Buntoonprayuk 2026), two reports on 120 women, which may describe the same trial, used 80 mg a day of a nanomicelle form for 6 months (Kheiridoost 2022; Sadeghzadeh 2023), and a Japanese pilot used 150 mg a day for 8 weeks (Sugawara 2012). No trial compared doses, and the 2025 meta-analysis noted that curcumin purity and dose varied between trials (Jin 2025).

Standard curcumin is poorly absorbed, so many products add piperine (black pepper extract) or use other high-absorption forms. NCCIH says conventional curcumin is likely safe in recommended amounts for up to 2 or 3 months, and that liver damage has been reported with bioavailable formulations (NCCIH 2025). A plain product at a trial dose, for a limited period, is the cautious choice.

In a 2020 triple-blind trial of 93 postmenopausal women in Iran, 500 mg curcumin twice a day for 8 weeks made no difference to overall menopause symptoms (Greene Climacteric Scale), anxiety or sexual function compared with placebo, although hot flashes fell (Ataei-Almanghadim 2020). A 2022 trial from the same group (84 women, same dose) found symptom scores fell in all groups, placebo included, with no symptom advantage for curcumin (Farshbaf-Khalili 2022).

In 74 women given the same dose, depression scores did not differ from placebo (p = 0.245) (Shabani 2025). In the Thai pilot, total MENQOL and MRS II scores did not differ from placebo at 12 weeks (Buntoonprayuk 2026). The 2025 systematic review concluded that curcumin had no significant effects on physical, psychological or sexual function (Akyakar 2025).

Hot flashes are the most promising symptom, though the evidence is thin. Curcumin lowered hot flash counts in the 93-woman Iranian trial (adjusted mean difference -10.7, P = 0.001) (Ataei-Almanghadim 2020) and by 7.35 a week more than placebo in the 40-woman Thai pilot (p < 0.001) (Buntoonprayuk 2026). A 2024 trial from the Iranian group reported a hot flash benefit for vitamin E but no hot flash result for curcumin (Yousefi-Nodeh 2024). The 2025 meta-analysis pooled a small vasomotor improvement (SMD -0.39) (Jin 2025). Our curcumin for hot flashes page covers these trials in detail.

In a 2025 trial of 74 women, 8 weeks of curcumin improved musculoskeletal health scores (mean difference 5.3, p < 0.001), just short of the minimum clinically important difference, and lowered fatigue scores (mean difference -2.6, p < 0.001) compared with placebo (Shabani 2025). It is a single trial, and some participants dropped out with stomach ache or headache.

The 2025 meta-analysis of 14 trials (982 participants) found curcumin lowered systolic (SMD -0.51) and diastolic (SMD -0.63) blood pressure in postmenopausal women (Jin 2025). In an 8-week Japanese pilot of 45 women, though, 150 mg curcumin a day lowered aortic systolic pressure only when combined with endurance exercise, not on its own (Sugawara 2012). A 2024 systematic review of four clinical trials called the vascular results preliminary (Mad Azli 2024). See high blood pressure for treatments with stronger evidence.

In 84 women, curcumin lowered fasting blood glucose (P = 0.007), total cholesterol (P = 0.015) and triglycerides (P = 0.007) compared with placebo over 8 weeks (Yousefi-Nodeh 2024). The 2025 systematic review found short-term curcumin had no significant cardiometabolic effects, while long-term use of bioavailable forms improved glucose, insulin, insulin resistance and lipids (Akyakar 2025). In a 6-month trial of 80 mg nanomicelle curcumin, the differences from placebo were significant for blood sugar measures (Sadeghzadeh 2023).

In a 12-month trial of 60 postmenopausal women with osteoporosis, adding curcumin to alendronate improved bone mineral density at four sites and bone turnover markers more than alendronate alone; the abstract does not give the curcumin dose (Khanizadeh 2018). In a larger 6-month trial of 120 women with osteoporosis or osteopenia, all taking alendronate, calcium and vitamin D, 80 mg nanomicelle curcumin alone did not change bone turnover markers compared with placebo; only its combination with Nigella sativa oil lowered alkaline phosphatase (Kheiridoost 2022).

The 2025 systematic review called the bone marker results conflicting (Akyakar 2025). The North American Menopause Society says hormone therapy has been shown to prevent bone loss and fracture (NAMS 2022), and no curcumin trial measured fractures.

In the menopause trials, curcumin was generally well tolerated. All 40 women in the Thai pilot completed it with no serious adverse events (Buntoonprayuk 2026), and in a 6-month trial liver enzymes and kidney markers showed no toxicity at 80 mg nanomicelle curcumin a day (Kheiridoost 2022). Some women in an 8-week trial dropped out with stomach ache or headache (Shabani 2025). NCCIH lists nausea, vomiting, acid reflux, stomach upset, diarrhoea and constipation as possible side effects, and says turmeric supplements may be unsafe during pregnancy, which is still possible in perimenopause (NCCIH 2025).

The rare but serious risk is liver injury. A US registry found 10 cases of turmeric-associated liver injury; 8 were women, the median age was 56, 5 were hospitalised and 1 died. Injury appeared 1 to 4 months after starting, and 3 of the 7 products tested also contained piperine (Halegoua-DeMarzio 2023). NCCIH advises stopping turmeric or curcumin immediately and talking with your provider if you notice fatigue, nausea, poor appetite, dark urine or jaundice (NCCIH 2025).

Tamoxifen is the interaction that matters most for women around menopause with a history of breast cancer. In patients taking tamoxifen, levels of its active form, endoxifen, fell by 7.7% with curcumin at 1,200 mg three times a day (not statistically significant, p = 0.07) and by 12.4% with curcumin plus piperine (p = 0.02). The authors warned this could push some patients below the effective level (Hussaarts 2019). In women with joint pain from aromatase inhibitors, a nanoemulsion curcumin did no better than placebo on symptoms, pain or grip strength over 3 months; that trial looked for benefit, not for a drug interaction (Lustberg 2024).

A French case report described a probable interaction in which turmeric raised the INR (a measure of blood clotting time) in a patient taking the vitamin K antagonist fluindione (Daveluy 2014). NCCIH advises talking with your provider before using any herbal product if you take medicines (NCCIH 2025). See breast cancer for more on supplements during treatment.